Uses of Dotiric 2: For the treatment of gout and hyperuricemia. It is indicated for the treatment of gout and hyperuricemia. Dotiric 2 is contraindicated in patients with known hypersensitivity to the drug component.

How to use Dotinurad: _NAME_ administered orally once daily. The maintenance dose is usually 2 mg once a day and maximum dose should be 4 mg once a day. Administration: Dotinurad is administered orally. The maximum dose should be 4 mg once a day. Adult Dose: The usual adult dosage is 0.5 mg of Dotinurad. In the early stages of treatment with urate-lowering drugs, gouty arthritis (gout attack) may be induced by a rapid decrease in blood uric acid levels. The dose should be gradually increased to 1 mg once a day after 2 weeks and 2 mg once a day after 6 weeks. Patients should be carefully monitored after the dose is increased. If you accidentally take too much, consult your doctor or pharmacist. Child Dose: Not recommended for children. Renal Dose: Consider treatment with other agents. Since this drug acts in the renal proximal tubule, its efficacy may be reduced depending on the degree of renal dysfunction. In particular, administration of this drug should be avoided in patients with oliguria or anuria, as its efficacy cannot be expected.

Pyrazinamide: The effect of this drug may be weakened. Pyrazinamide is known to suppress uric acid secretion in renal tubules and may antagonize the promotion of uric acid excretion by this drug. Salicylic acid preparations Aspirin: Salicylic acid preparations are known to suppress uric acid excretion and may antagonize the promotion of uric acid excretion by this drug.

Dotinurad is contraindicated in patients with known hypersensitivity to the drug component.

The most common side effects are gouty arthritis, limb discomfort (1% to less than 5%). (Loose stools, increased y-GTP, arthralgia, kidney stones, nephrocalcinosis, increased urinary y2 macroglobulin, increased blood creatinine, increased urine albumin/creatinine ratio, positive urine albumin) has been reported in less than 1% patients. Common side effects are: gouty arthritis, limb discomfort (1% to less than 5%). (Loose stools, increased y-GTP, arthralgia, kidney stones, nephrocalcinosis, increased urinary y2 macroglobulin, increased blood creatinine, increased urine albumin/creatinine ratio, positive urine albumin) has been reported in less than 1% patients.

Precaution: This drug is a uric acid-lowering drug and lowering the blood uric acid level at the onset of gouty arthritis (gouty attack) may exacerbate gouty arthritis (gouty attack). If gouty arthritis (gout attack) is observed before administration of this drug, administration of this drug should not be started until the symptoms subside. In addition, if gouty arthritis (gouty attack) occurs during administration of this drug, administration should be continued without changing the dose of this drug and colchicine, non-steroidal anti-inflammatory drugs, corticosteroids etc. may be administered depending on the symptoms. Use together.

Dotinurad is a URAT1-selective urate reabsorption inhibitor that selectively inhibits URAT1 and inhibits urate reabsorption, thereby increasing urinary urate excretion and lowering serum urate levels. In addition, since it has weak inhibitory effects on ABCG2, OAT1 and OAT3 other than URAT143,44, it is expected to effectively lower serum uric acid levels without affecting uric acid secretion via these transporters. Thus, Dotinurad is a selective urate reabsorption inhibitor (SURI) that inhibits the reabsorption pathway mediated by URAT1 without inhibiting the uric acid secretion pathway mediated by ABCG2, OAT1 and OAT3 because of its high URAT1 selectivity.

During pregnancy, Dotinurad should only be treated if the therapeutic benefits are judged to outweigh the risks.